AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
BridgeBio Pharma, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00P9KDZL5
68.56▲ 0.44 (0.65%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
68.12
Day's Range
67.02 – 68.86
52-Week Range
52.75 – 93.42
Volume
2.4M
Avg Volume
2.9M
Share Statistics
Shares Outstanding
Employees
839
Exchange
XNAS
Listed
2019-06-27
Share count as of August 3, 2026

BridgeBio Pharma, Inc. Common Stock (BBIO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about BridgeBio Pharma, Inc. Common Stock (BBIO)
What is BridgeBio Pharma, Inc. Common Stock's Market Cap?
BridgeBio Pharma, Inc. Common Stock's Market Cap is $13.4B, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's Enterprise Value?
BridgeBio Pharma, Inc. Common Stock's Enterprise Value is $15.4B, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's Price / Sales?
BridgeBio Pharma, Inc. Common Stock's Price / Sales is 18.8×, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's EV / Revenue?
BridgeBio Pharma, Inc. Common Stock's EV / Revenue is 21.6×, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's EV / EBITDA?
BridgeBio Pharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's Revenue (TTM)?
BridgeBio Pharma, Inc. Common Stock's Revenue (TTM) is $713.1M, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's Net Income (TTM)?
BridgeBio Pharma, Inc. Common Stock's Net Income (TTM) is -$702.0M, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's EBITDA?
BridgeBio Pharma, Inc. Common Stock's EBITDA is -$492.7M, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's Diluted EPS (TTM)?
BridgeBio Pharma, Inc. Common Stock's Diluted EPS (TTM) is -3.59, based on as-reported figures from SEC (XBRL) filings.
What is BridgeBio Pharma, Inc. Common Stock's EBITDA Margin?
BridgeBio Pharma, Inc. Common Stock's EBITDA Margin is -69.1%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · BBIOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues, net
YoY growth+120.4%+66.8%+2521.2%+4318.0%
Cost of revenues:
Total cost of revenues
Research and development
Selling, general and administrative
Restructuring, impairment, and related charges
Total operating costs and expenses
% of revenue143.9%154.5%190.5%220.3%
Loss from operations
% of revenue-43.9%-54.5%-90.5%-120.3%
Other income (expense), net:
Interest income
Interest expense
Noncash interest expense on deferred royalty obligations
Loss on extinguishment of debt
Net loss from equity method investments
Net loss
% of revenue-64.0%-85.6%-126.2%-153.2%
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests
Net loss attributable to common stockholders of BridgeBio
Net loss per share attributable to common stockholders of BridgeBio, basic (in dollars per share)
Net loss per share attributable to common stockholders of BridgeBio, diluted (in dollars per share)